About Wellesley Pharmaceuticals
Wellesley Pharmaceuticals, LLC was founded to ensure that the ability of Nocturol to reduce and sometimes eliminate nocturia symptoms can be disseminated to help the hundreds of millions of people who can benefit from it.
Nocturol’s ability to reduce bathroom visits is now supported by 10 issued US method-of-use patents that have been granted. Patent protection around the world is underway with patents already having been granted in Australia, New Zealand, Russia, Singapore, South Africa, and Taiwan.
The company also has a patent pending for a lower dose version of Nocturol that could be helpful for children who wet their beds. About 3.2 million children ages 5-14 in the US wet their beds on a regular basis. These children are likely to be treated successfully with Nocturol since most nocturia sufferers and bedwetters share the same underlying cause, which is elevated prostaglandin levels.
Bedwetting causes social problems, an average of $1,000 per year in extra laundry costs, and can sometimes even lead to child abuse.
Contact us if you need more information about Wellesley Pharmaceuticals or Nocturol.
PLEASE NOTE THAT NOCTUROL HAS NOT BEEN APPROVED BY THE FDA OR EMA OR ANY OTHER REGULATORY AUTHORITY. NOCTUROL IS CURRENTLY UNDERGOING A PHASE 2 CLINICAL TRIAL.